Compare Fubotv Inc (FUBO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $9.83 (market cap $1.06B), while Regeneron Pharmaceuticals Inc trades at $792.89 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 77.4× Fubotv Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | REGN | |
|---|---|---|
Market Cap | $1.06B | $82.06B |
Sector | Technology | Health |
52-Week High | $54.72 | $812.27 |
52-Week Low | $8.09 | $555.51 |
Enterprise Value | $1.23B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.36, up 1.08% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growing to $1.62B in 2024 and projected net income turning positive at $123M for 2025. Recent CEO transition to former Disney executive Alisa Bowen and partnerships with major media companies signal strategic repositioning.
While valuation metrics appear attractive with P/E of 2.53 and P/S of 0.19, the stock faces execution risks in achieving profitability targets. Analyst consensus is mixed with 46.7% buy ratings and $15.33 price target, representing significant upside potential if the company can deliver on its EBITDA growth roadmap.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
